UA91057C2 - Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли - Google Patents

Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли

Info

Publication number
UA91057C2
UA91057C2 UAA200714103A UAA200714103A UA91057C2 UA 91057 C2 UA91057 C2 UA 91057C2 UA A200714103 A UAA200714103 A UA A200714103A UA A200714103 A UAA200714103 A UA A200714103A UA 91057 C2 UA91057 C2 UA 91057C2
Authority
UA
Ukraine
Prior art keywords
oligonucleotide
composition
treating
same
functional homologue
Prior art date
Application number
UAA200714103A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ли-ин Ван
Му-шен Бао
Юн-ли Юй
Original Assignee
Чанчунь Хуапу Байотекнолоджи Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чанчунь Хуапу Байотекнолоджи Ко., Лтд. filed Critical Чанчунь Хуапу Байотекнолоджи Ко., Лтд.
Publication of UA91057C2 publication Critical patent/UA91057C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/313Phosphorodithioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
UAA200714103A 2005-05-17 2006-02-13 Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли UA91057C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2005100695764A CN1865275B (zh) 2005-05-17 2005-05-17 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸

Publications (1)

Publication Number Publication Date
UA91057C2 true UA91057C2 (ru) 2010-06-25

Family

ID=37424439

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200714106A UA94231C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
UAA200714103A UA91057C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA200714106A UA94231C2 (ru) 2005-05-17 2006-02-13 Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли

Country Status (22)

Country Link
US (3) US20090202567A1 (ru)
EP (2) EP1883647B1 (ru)
JP (2) JP4837034B2 (ru)
KR (2) KR101294131B1 (ru)
CN (1) CN1865275B (ru)
AU (2) AU2006246897B2 (ru)
BR (2) BRPI0609882A2 (ru)
CA (2) CA2609067A1 (ru)
CY (1) CY1114844T1 (ru)
DK (2) DK1883411T3 (ru)
ES (2) ES2442462T3 (ru)
HK (2) HK1113318A1 (ru)
IL (2) IL187281A (ru)
MX (2) MX2007014145A (ru)
NZ (1) NZ563582A (ru)
PL (2) PL1883411T3 (ru)
PT (2) PT1883411E (ru)
RU (2) RU2413519C2 (ru)
SI (2) SI1883411T1 (ru)
UA (2) UA94231C2 (ru)
WO (2) WO2006122464A1 (ru)
ZA (2) ZA200710311B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728276A1 (en) * 2008-06-18 2009-12-23 Index Pharmaceuticals Ab Combination therapies against cancer
CN101643496B (zh) * 2008-08-07 2015-09-09 长春华普生物技术有限公司 一种具有免疫抑制功能的寡核苷酸
EP2350282A1 (en) * 2008-11-04 2011-08-03 Index Pharmaceuticals AB Increased expression of specific antigens
ES2870458T3 (es) * 2010-12-21 2021-10-27 Index Pharmaceuticals Ab Oligonucleótidos biológicamente activos capaces de modular el sistema inmunitario
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
CN106893724B (zh) * 2015-12-17 2023-05-02 苏州派动生物技术有限公司 具有抗原增效作用和肿瘤治疗作用的寡核苷酸
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60022665T2 (de) 1999-09-25 2006-06-22 Coley Pharmaceutical Gmbh Immunstimulierende nukeinsäuren
JP2004500412A (ja) * 2000-03-31 2004-01-08 アイデック ファーマスーティカルズ コーポレイション B細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗cd20の併用
DE60139689D1 (de) * 2000-06-22 2009-10-08 Univ Iowa Res Found Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
US20040009156A1 (en) 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US8080554B2 (en) 2001-12-12 2011-12-20 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
DE10258677A1 (de) 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
CN100486987C (zh) * 2003-03-05 2009-05-13 长春华普生物技术有限公司 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸
CN100439386C (zh) 2003-03-05 2008-12-03 长春华普生物技术有限公司 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
ATE532792T1 (de) 2003-07-25 2011-11-15 Changchun Huapu Biotechnology Co Ltd Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen
JP4513879B2 (ja) 2008-03-05 2010-07-28 ソニー株式会社 像ぶれ補正装置、レンズ鏡筒装置及びカメラ装置

Also Published As

Publication number Publication date
EP1883647A4 (en) 2010-10-06
EP1883411B1 (en) 2013-08-14
US8450292B2 (en) 2013-05-28
CN1865275B (zh) 2011-06-15
AU2006246898A1 (en) 2006-11-23
AU2006246897A1 (en) 2006-11-23
SI1883647T1 (sl) 2014-02-28
EP1883411A1 (en) 2008-02-06
DK1883647T3 (da) 2014-01-27
CA2609062C (en) 2013-11-19
IL187249A0 (en) 2008-02-09
MX2007014145A (es) 2008-03-07
PT1883647E (pt) 2014-01-20
AU2006246897B2 (en) 2012-04-12
RU2409672C2 (ru) 2011-01-20
ZA200710311B (en) 2009-08-26
JP2008539767A (ja) 2008-11-20
US20090202567A1 (en) 2009-08-13
US20120142761A1 (en) 2012-06-07
DK1883411T3 (da) 2013-11-18
MX2007014146A (es) 2008-03-07
KR20080007655A (ko) 2008-01-22
IL187249A (en) 2012-03-29
BRPI0609885A2 (pt) 2010-05-04
CA2609062A1 (en) 2006-11-23
WO2006122463A1 (en) 2006-11-23
EP1883411A4 (en) 2010-10-06
US8133874B2 (en) 2012-03-13
KR101346716B1 (ko) 2014-01-02
NZ563582A (en) 2010-04-30
RU2007146706A (ru) 2009-06-27
BRPI0609882A2 (pt) 2010-05-04
PL1883411T3 (pl) 2014-01-31
RU2413519C2 (ru) 2011-03-10
US20090162279A1 (en) 2009-06-25
EP1883647B1 (en) 2013-10-23
HK1113318A1 (en) 2008-10-03
CN1865275A (zh) 2006-11-22
WO2006122464A1 (en) 2006-11-23
ES2442462T3 (es) 2014-02-11
ES2433129T3 (es) 2013-12-09
JP4837034B2 (ja) 2011-12-14
IL187281A0 (en) 2011-08-01
ZA200710312B (en) 2009-08-26
KR20080011426A (ko) 2008-02-04
CA2609067A1 (en) 2006-11-23
JP2008539768A (ja) 2008-11-20
AU2006246898B2 (en) 2011-08-18
KR101294131B1 (ko) 2013-08-07
CY1114844T1 (el) 2016-12-14
SI1883411T1 (sl) 2014-01-31
RU2007146705A (ru) 2009-06-27
UA94231C2 (ru) 2011-04-26
JP4837033B2 (ja) 2011-12-14
EP1883647A1 (en) 2008-02-06
IL187281A (en) 2012-04-30
PL1883647T3 (pl) 2014-03-31
PT1883411E (pt) 2013-11-11
HK1112745A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
NL301145I1 (ru)
UA91057C2 (ru) Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли
HK1088024A1 (en) Hydrophilized blocked polyisocyanates
GB0400584D0 (en) Nucleic acid chacterisation
WO2004022714A3 (en) Organic species that facilitate charge transfer to or from nanostructures
IL164228A0 (en) Antisense iap nucleobase oligomers and uses thereof
GB2462020A (en) Systems, methods, and processes for use in treating subsurface formations
EP1750771A4 (en) PANCREATIC ILOT MICRO-RNA AND METHODS OF INHIBITING THE SAME
MX2010003606A (es) Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
MX2009006252A (es) Sal de tanato de rasagilina.
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
TW200716132A (en) Novel chemical compounds
TW200630348A (en) Tadalafil crystal forms and processes for preparing them
WO2020207510A3 (zh) 基因在促进水稻籽粒产量上的应用
PL1948689T3 (pl) Mutanty czynników wzrostu o wysokiej aktywności
UA91733C2 (ru) Способ получения кристаллической формы орлистата
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
BRPI0308119A2 (pt) microorganismo como portadores de seqüências de nucleotídeos codificando para antígenos de células para o tratamento de tumores.
UA83203C2 (ru) Тиазол-(би)циклоалкилкарбоксанилиды, средство на их основе и применение для борьбы с нежелательными микроорганизмами
WO2003104397A3 (en) ANTISENSE MODULATION OF PROTEIN KINASE GR 6 EXPRESSION
GB0514502D0 (en) Substituted organopolysiloxanes containing phosphonic groups,method for the production and use thereof
TW200716579A (en) Novel chemical compounds
MY136360A (en) Cyclohexane derivatives and methods for their preparation
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof